What is the role of upfront addition of an ALK inhibitor in an ALK positive mature B Cell lymphoma in an AYA patient?
Answer from: at Community Practice
Crizotinib has gained FDA approval in pediatric patients > 1 as monotherapy for relapsed anaplastic large cell lymphoma (ALK+) based on the COG ADVL0912 study. The agent was subsequently studied in upfront ALCL with aggressive chemotherapy based on the European ALCL99 regimen in ANHL12P1 but ther...
Sign in or Register to read more